Christina Mattina

Renal denervation modestly lowers blood pressure, with durable long-term benefits, according to Deepak L. Bhatt, MD, MPH, MBA.

Cutting-edge therapies can help move the treatment landscape forward, but basic treatment and prevention, such as smoking cessation, are still valuable means of addressing non–small cell lung cancer (NSCLC).

The study found no difference in physician communication scores between patients with advanced cancer and other illnesses, suggesting that discordance may stem from other dynamics.

Jonathan Thompson, MD, MS, explains how financial, insurance, and socioeconomic barriers limit equitable access to biomarker testing and advanced therapies, underscoring the need for provider advocacy and systemic support.

A clinical trial assessing a remote weight loss intervention in women with breast cancer saw a reduction in body weight.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

Ravi Vij, MD, MBA, explains how insurance-related delays in CAR T approval slow treatment initiation, increase interim therapy costs, and contribute to patient burden.

Treatment challenges that Anasuya Gunturi, MD, PhD, encounters in her work at Lowell General Hospital include language differences and confusion about scheduled appointments.

Rising metabolic score for insulin resistance (METS-IR) levels strongly correlate with major cardiovascular events (MACE) and mortality in patients with type 2 diabetes (T2D), according to one study.

A new study finds that drugmakers’ use of overlapping patents delayed generic entry for 4 top-selling drugs, driving billions in excess spending.

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan and the European Union following later that year and 2025, respectively.

Couples that were made up of 2 transgender women were less likely to contract HIV compared with couples that were made up of a transgender woman and a cisgender man.

The American Society for Preventive Cardiology (ASPC) marked its 40th anniversary this year at the ASPC Congress on CVD Prevention in Boston, held August 1-3, with 3 days of debates, presentations, oral abstracts, and posters.

In this study, total flares were investigated for their propensity to predict atopic dermatitis disease severity among adult patients.

New research reveals how triple-negative breast tumors use fatty tissue to fuel growth, highlighting the role of gap junctions in tumorigenesis.

Jonathan Thompson, MD, MS, highlighted that reducing delays in molecular testing and treatment initiation is critical for improving lung cancer outcomes, and that clinical trial data suggest immunotherapy duration can often be safely de-escalated in patients who achieve a complete pathologic response.

A UK cohort study finds socioeconomic deprivation in early life is tied to greater eating disorder symptoms in adolescence, with barriers to care.

A novel image-based deep learning approach achieves high accuracy and interpretability, offering potential for clinical decision support.

Health systems must prepare for the growing impact of cell and gene therapies by addressing their high costs, complex care pathways, and payer collaboration needs to ensure timely and sustainable patient access.

The FDA approved zopapogene imadenovec, the first therapy for recurrent respiratory papillomatosis, providing an option beyond repeated surgeries to manage the rare condition.

This approval brings the total to 4 of medications approved to treat fibromyalgia; in addition to cyclobenzaprine HCl sublingual tablets (TNX-102 SL; Tonmya; Tonix Pharmaceuticals), there are pregabalin (Lyrica; Viatris), duloxetine (Cymbalta; Eli Lilly), and milnacipran (Savella; AbbVie).

Emilie Aschenbrenner, PharmD, BCOP, outlines how Froedtert Health and the Medical College of Wisconsin use outpatient-based care models, standardized protocols, and collaborative partnerships to improve cost-effectiveness, accessibility, and patient experience.

Approval was based on part 1 of the ESSENCE trial, with part 2 results expected in 2029.

Clayton Irvine, PharmD, MBA, MS, discusses how pharmacists are essential to advancing payer–provider collaboration in value-based care by shaping formularies, standardizing drug reviews, leveraging real-world evidence, and leading pilot programs to optimize patient outcomes and cost-effectiveness.

A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) receptor agonist use.

Clayton Irvine, PharmD, MBA, MS, emphasized that optimizing value-based access to cell and gene therapies requires standardized care protocols, coordinated transitions between care settings, careful evaluation of prior authorization and financial assistance options, and formulary decisions that balance clinical outcomes with both direct and indirect costs to patients and institutions.

Selected patients with a clinical response after therapy could benefit from salvage surgery in non–small cell lung cancer (NSCLC), with acceptable results for perioperative morbidity.

Emilie Aschenbrenner, PharmD, BCOP, discusses how integrating CD38-targeted therapies into first-line treatment for transplant-ineligible multiple myeloma requires balancing clinical benefit, cost, and insurance coverage.

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).